Overview
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Aim of study is to provide safety and tolerability data on enteric-coated mycophenolate sodium in regard to adverse events, serious adverse events and patient and graft survival. After successful completion of the study CERL080A0107 study, patients could continue to receive enteric-coated mycophenolate sodium.Phase:
Phase 3Details
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Mycophenolate mofetil
Mycophenolic Acid
Criteria
Inclusion Criteria:- Cadaveric or living donor kidney transplant recipients who completed the study
CERL080A0107
Exclusion Criteria:
- Other protocol-defined inclusion/exclusion criteria may apply.